


PRODUCT LIST



COMPANY PROFILE

THE LEADING PEPTIDE MANUFACTURER IN ASIA



Hainan Zhonghe Pharmaceutical Co., Ltd, established in 1995, is the first high-tech enterprise specialized in development, production and marketing of peptide drugs in China.

The manufacturing site is located in south China. All the premises were designed and constructed strictly in compliance with GMP requirements. All the production lines, including small volume parenteral solution, lyophilized powder for injection and oral solid dosage forms, are GMP certified. Some of them successfully passed GMP audit by PIC/S members.

In 1997, HEXIN[®] Thymopentin for injection, the first peptide drug developed by Zhonghe, was approved and launched, which marked the beginning of the peptide industry in China. Since then, diversified peptide products were launched in succession, covering many therapeutic areas such as the immune system, antineoplastic, hepatopathy, digestive system, urinary system, gynecology and obstetrics etc.

With the goal of 'manufacturing the best peptide medicine for the patients', Zhonghe takes the product's quality as the life of the enterprise. Due to advanced high-tech machinery and strict procedures to meet GMP standards we can confidently say that Zhonghe has never gone through any issue that put at stake the quality of our products. Superior quality has made of Zhonghe the foremost brand in the domestic field of synthetic peptide drugs, ranking among the best 10 pharmaceutical firms in this industry. Zhonghe also pays much attention to the global market. Our products have been registered in South Korea (PIC/S member), Hong Kong (PIC/S member), Macau, ASEAN countries, Uzbekistan, among others. As an evidence to the reliability of our products, we can gladly say that since 2016 our product HERI[®] surpassed the originator brand (Zadaxin) in sales volume share in the South Korean market.

Besides our constant efforts to enhance human health, Zhonghe has also been committed to its Corporate Social Responsibility through different donations to cultural practices, education and scientific research. During the SARS (severe acute respiratory syndrome) epidemic in 2003, as a bidirectional immune modulator, Hexin[®] Thymopentin was prescribed as a first-line anti-SARS drug and proved to be effective against this infection. In this condition Zhonghe donated medicine valued at more than 1 million US dollars helping thousands of patients to recover successfully.

Dedication and consistency create specialized knowledge, based on this principal Zhonghe will continue to enhance and dedicate more time, resources and effort to the health care of human beings.



[INN in English]

Thymopentin

[Clinical Usage]

- Supplementary treatment of tumor diseases.
- Acute and chronic hepatitis.
- Various primary or secondary T cell immunodeficiency diseases.
- Certain auto-immune diseases.
- Various diseases with impaired cell immunity functions.

[Strength]

- (1) 1 mg, 10 mg (Thymopentin for injection)
- (2) 1 ml : 1 mg, 1 ml : 10 mg (Thymopentin injection)
- (3) 1 ml : 1 mg, 1 ml : 10 mg (Thymopentin prefilled injection)



**HEXIN[®] Thymopentin Injection
/ Thymopentin for Injection**

[INN in English]

Thymalfasin

[Clinical Usage]

- Chronic hepatitis B.
- Immune response enhancer.
- Malignant tumors.
- Infectious diseases.

[Strength]

1.6 mg



HERI[®] Thymalfasin for Injection
(Thymosin α 1 for injection)

[INN in English]

Atosiban

[Clinical Usage]

- Delay imminent pre-term birth in pregnant adult women.
- In vitro fertilization and embryo transfer.

[Strength]

(1) 0.9 ml : 6.75 mg

(2) 5 ml : 37.5 mg



HESHUANG[®] Atosiban Acetate Injection

[INN in English]

Entecavir

[Clinical Usage]

- Chronic hepatitis B.

[Strength]

0.5 mg



HEDING[®] Entecavir Capsules
HEEN[®] Entecavir Dispersible Tablets

[INN in English]


Octreotide

[Clinical Usage]

- Acromegaly.
- Gastrointestinal and pancreatic endocrine tumor.
- Prevention of complications of pancreatic surgery.
- Bleeding from esophageal-gastric varices.

[Strength]

- (1) 1 ml : 0.05 mg
- (2) 1 ml : 0.1 mg
- (3) 1 ml : 0.3 mg



HEQI[®] Octreotide Acetate Injection

[INN in English]

Somatostatin

[Clinical Usage]

- Severe acute haemorrhage from esophageal varices.
- Severe acute haemorrhage from gastric or duodenal ulcers.
- Prophylaxis and treatment of postoperative complications following pancreatic surgery.
- Adjuvant treatment in pancreatic, biliary, intestinal fistulae, and diabetic ketoacidosis.

[Strength]

3.0 mg



HENING[®] Somatostatin for Injection

[INN in English]

Desmopressin

[Clinical Usage]

- The prevention of bleeding in patients with mild hemophilia A and mild von Willebrand's disease Type I.
- The prevention or treatment of bleeding in patients before therapeutic intervention or diagnosed operation.
- Central diabetes insipidus.
- Renal concentrating capacity test.

[Strength]

- (1) 1 ml : 4 μ g
- (2) 1 ml : 15 μ g



HEYI[®] Desmopressin Acetate Injection

[INN in English]

Desmopressin

[Clinical Usage]

- Central diabetes insipidus.
- Primary nocturnal enuresis.

[Strength]

- (1) 0.1 mg
- (2) 0.2 mg



HEYUE[®] Desmopressin Acetate Tablets

Latest Arrivals to Our Portfolio

In-House Manufactured Finished Dosage Forms (FDF) on Sale

PIC/S GMP

[INN in English]

Eptifibatide

[Clinical Usage]

- Platelet aggregation.

[Strength]

(1) 20 mg/10 mL



HEYI® Eptifibatide Injection

In-House Manufactured API on Sale

No.	INN in English	Clinical Usage
1	Thymalfasin	Cancer, hepatitis.
2	Desmopressin acetate	Surgical bleeding and Anti-diuresis.
3	Octreotide acetate	Gastrointestinal hemorrhage.
4	Atosiban acetate	Premature labor.
5	Cetrorelix acetate	Inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Finished Dosage Forms (FDF) Under Development

No.	Product Name	INN in English	Strength	Clinical Usage
1	Cetrorelix Acetate for Injection	Cetrorelix	0.25 mg	Inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
2	Tenofovir Alafenamide Fumarate tablets	Tenofovir Alafenamide Fumarate	25 mg	Chronic hepatitis B.
3	Carbetocin injection	Carbetocin	1ml:100µg	Prevention of uterine atony and postpartum hemorrhage.
4	Bivalirudin injection	Bivalirudin	0.25g	Anticoagulant in patients undergoing percutaneous coronary intervention.

API Under Development

No.	INN in English	Clinical Usage
1	Thymopentin	Immune modulator.
2	Carbetocin	Prevention of uterine atony and postpartum hemorrhage.
3	Bivalirudin	Anticoagulant in patients undergoing percutaneous coronary intervention.
4	Ganirelix Acetate	Inhibition of premature LH surges in women undergoing controlled ovarian hyper stimulation.

CONCENTRATED

in peptide industry, improve life quality



HAINAN ZHONGHE PHARMACEUTICAL CO.,LTD.

Add: Free Trade Zone, 168 Nanhai Avenue, Haikou 570216, Hainan, P. R. China

Tel: +86-898-66802207 Fax: +86-898-66802211

E-mail: lizhongjing@zhonghe.cn

www.zhonghe.cn

